Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Droloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 14/20 | 0.80 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.80 |
| ▸ | ESRRG | P62508 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | PGR | P06401 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.80 |
| ▸ | ESRRB | O95718 | 2/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.80 |
| ▸ | PLD2 | O14939 | 1/20 | 0.80 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Droloxifene SCHEMBL750110 | 1.00 | ESR1 (0.80) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL9782633 | 1.00 | ESR1 (0.80) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL28095329 | 1.00 | ESR1 (0.80) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL28095331 | 1.00 | ESR1 (0.80) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL5030004 | 0.99 | ESR1 (0.82) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL4842 | 0.99 | ESR1 (0.82) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL30534774 | 0.99 | ESR1 (0.82) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL30728607 | 0.99 | ESR1 (0.82) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL1151787 | 0.99 | ESR1 (0.82) | ESR1ESR2ESRRGMAPTMEN1 | |
| Droloxifene SCHEMBL4843 | 0.99 | ESR1 (0.82) | ESR1ESR2ESRRGMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578587-B1 | PYRAZOLE DERIVATIVES | HANDE STARLAKE BIOSCIENCE CO LTD (CN) | 2016-09-07 | — | — | EP | claimed |
| US-9249172-B2 | Pyrazole derivatives | HANDE PHARMA LIMITED (CN) | 2016-02-02 | — | — | US | claimed |
| US-20130142757-A1 | PYRAZOLE DERIVATIVES | HANDE STARLAKE BIOSCIENCE CO., LTD. (CN) | 2013-06-06 | — | — | US | claimed |
| EP-2578587-A1 | PYRAZOLE DERIVATIVES | Hande Starlake Bioscience Co., Ltd. (CN) | 2013-04-10 | — | — | EP | claimed |
| US-10611775-B2 | Thiophene derivatives | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2020-04-07 | — | — | US | disclosed |
| US-20190322684-A1 | THIOPHENE DERIVATIVES | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2019-10-24 | — | — | US | disclosed |
| US-10385062-B2 | Thiophene derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-08-20 | — | — | US | disclosed |
| CN-104955459-B | Substituted indoles -5- amphyl and its treatment use | 南特知识产权控股有限责任公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-105101959-B | Cyclic sulfonamide-containing derivatives as hedgehog signaling pathway inhibitors | 南特知识产权控股有限责任公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107530346-A | The solvation form of bruton's tyrosine kinase inhibitor | 药品循环有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107530347-A | The co-crystal thereof of bruton's tyrosine kinase inhibitor | 药品循环有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20170197982-A1 | THIOPHENE DERIVATIVES | GANZHOU HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2017-07-13 | — | — | US | disclosed |
| EP-2431371-B1 | THIOPHENE DERIVATIVES | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2013-10-09 | — | — | EP | disclosed |
| US-20130142757-A1 | PYRAZOLE DERIVATIVES | HANDE STARLAKE BIOSCIENCE CO., LTD. (CN) | 2013-06-06 | — | — | US | disclosed |
| EP-2578587-A1 | PYRAZOLE DERIVATIVES | Hande Starlake Bioscience Co., Ltd. (CN) | 2013-04-10 | — | — | EP | disclosed |
| US-20120107269-A1 | THIOPHENE DERIVATIVES | Tianjin Hemay Biotech Co., Ltd (CN) | 2012-05-03 | — | — | US | disclosed |
| EP-2431371-A1 | THIOPHENE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2012-03-21 | — | — | EP | disclosed |
| US-5047431-A | TREATMENT OF HORMONE-DEPENDENT MAMMARY TUMORS; ANTIESTROGENS | KLINGE PHARMA GMBH & CO. (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0054168-B1 | 1,1,2-TRIPHENYL-BUT-1-ENE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | Klinge Pharma GmbH (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0054168-A1 | 1,1,2-Triphenyl-but-1-ene derivatives, process for their manufacture and their use as pharmaceutical agents | Klinge Pharma GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385062-B2 | Thiophene derivatives | TSHR, RB1, TAS2R7 | ESR1 578/4885ESR2 452/4885ESRRG 364/4885 |
| US-20120107269-A1 | THIOPHENE DERIVATIVES | TSHR, RB1, TAS2R7 | ESR1 578/4885ESR2 452/4885ESRRG 364/4885 |
| US-10611775-B2 | Thiophene derivatives | TSHR, RB1, TAS2R7 | ESR1 578/4885ESR2 452/4885ESRRG 364/4885 |
| US-20170197982-A1 | THIOPHENE DERIVATIVES | TSHR, RB1, TAS2R7 | ESR1 578/4885ESR2 452/4885ESRRG 364/4885 |
| US-20130142757-A1 | PYRAZOLE DERIVATIVES | CBR3, CBR1, CYP2E1 | ESR1 1841/4885ESR2 590/4885ESRRG 143/4885 |
| US-20190322684-A1 | THIOPHENE DERIVATIVES | TSHR, RB1, TAS2R7 | ESR1 578/4885ESR2 452/4885ESRRG 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.